A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

10.1136/ijgc-2020-001604

Saved in:
Bibliographic Details
Main Authors: Ngoi, Natalie YL, Heong, Valerie, Ow, Samuel, Chay, Wen Yee, Kim, Hee Seung, Choi, Chel Hun, Goss, Geraldine, Goh, Jeffrey C, Tai, Bee Choo, Lim, Diana G, Kaliaperumal, Nivashini, Au, Veonice B, Connolly, John E, Kim, Jae-Weon, Friedlander, Michael, Kim, Kidong, Tan, David SP
Other Authors: MEDICINE
Format: Article
Language:English
Published: BMJ PUBLISHING GROUP 2020
Subjects:
Science & Technology
Life Sciences & Biomedicine
Oncology
Obstetrics & Gynecology
ANTITUMOR-ACTIVITY
SAFETY
Online Access:https://scholarbank.nus.edu.sg/handle/10635/177402
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English
Description
Summary:10.1136/ijgc-2020-001604

Similar Items